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Abstract
Background: Dual chamber pacing improves functional status and reduces left ventricular 
outflow tract gradients in some, but not all patients with hypertrophic cardiomyopathy (HCM) 
by altering ventricular depolarisation. We investigated the use of biventricular (BIV) pacing in 
symptomatic patients with HCM.                                                                                           
Method: 8 patients aged 58±7yrs with symptomatic HCM underwent BIV pacing. 5 patients 
had LVOT gradients >30mmHg. Ventricular electrodes were placed in the right ventricle (RV) 
and a branch of the coronary sinus. An atrial electrode was inserted to achieve BIV pacing 
with a short AV delay. The short-term effects of different pacing modalities were assessed 
using 2-D and Doppler echocardiography. Symptoms and exercise tolerance were assessed 
after a month of each pacing mode. Long-term follow up data was available for 5 years.    
Results: Baseline EF was 67±14% and mean QRS duration was 132±26msecs. BIV pacing 
reduced QRS duration compared to RV pacing (129±46 vs. 205±54msecs, p<0.005). Five of 
the seven patients had baseline LVOT gradients (mean 67±25mmHg) that decreased to 
41±15mm Hg with RV pacing (p<0.01) and 25±15mmHg with BIV pacing (p<0.005). 
Improvements in exercise time with active pacing occurred in six out of eight patients (75%), 
three (37.5%) had optimal exercise times with RV pacing and three with BIV pacing. Of the 
three patients with short term improvements with BIV pacing, one died 4 years post implant, 
one deteriorated with LV dilatation and one had the system explanted for infection.       
Conclusion: BIV pacing showed short-term beneficial effects in some patients over and above 
RV pacing alone. 
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Introduction
The mainstay of treatment for symptomatic patients with hypertrophic cardiomyopathy (HCM) 
is medical therapy, with surgical resection or alcohol septal ablation performed in patients with 
refractory symptoms and a significant left ventricular outflow tract (LVOT) gradient. Initial 
observational and uncontrolled studies reported benefits with dual chamber pacing with regard 
to symptoms and LVOT gradients [1-3]. This was thought in part to be due to altered LV 
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activation from RV apical pacing causing an increase in LV systolic diameter and reduced 
systolic anterior motion of the mitral valve and therefore reduced LVOT gradients. Later 
however, randomized cross-over trials reported less beneficial effects in terms of exercise 
capacity and LVOT gradient reductions [4-6]. There are in addition a number of patients who 
do not derive any benefit from dual chamber pacing, and as a result this treatment modality is 
reserved for severely symptomatic and medically refractory HCM patients with LV outflow 
obstruction [7]. We reported the first case of the beneficial effects of biventricular pacing in 
this patient population in terms of symptomatic status, exercise times and LV outflow tract 
gadients [8]. We hypothesized that some patients with HCM have evidence of intraventricular 
conduction delay which is increased by RV pacing and therefore could benefit from 
biventricular  pacing.  We  therefore  looked to  examine  its  role  in a  cohort of highly 
symptomatic patients over prolonged follow up.                                                                         
Methods
Patients:  The local research ethics committee approved the protocol and all patients gave 
written informed consent. Table 1 shows patient characteristics. All had symptomatic HCM 
despite medical therapy. Three patients had existing dual chamber pacemakers, 2 had 
undergone alcohol septal ablation and one a surgical myectomy. 7 patients (88%) had a QRS 
duration >120msecs and 5 patients had LVOT gradients >30mm Hg at rest. 
Table 1: Baseline patient characteristics
* Symptomatically better with BIV pacing but greater exercise time with RV pacing
Implantation of pacemaker: Implants were performed over the period from January 2001 to 
January 2002.  In 3 patients an existing DDD pacing system was upgraded. An atrial electrode 
was positioned in the right atrial appendage and a right ventricular pacing lead (if not already 
in situ) to the RV apex. A dedicated unipolar left heart pacing lead [Uni Aescula LV model 
1055K-(Pacesetter-St Jude)] was placed to a branch of the coronary sinus from which 
adequate pacing and sensing of the LV could be performed. The RV lead was positioned as far 
as possible from the LV lead.  A DDDR pulse generator capable of simultaneously pacing 
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both right and left ventricles was implanted in the left pectoral region. [Chorum 7336B DDDR 
(ELA Medical), Montrouge France, MSP in 7 patients, Medtronic In Sync III Medtronic, 
Minneapolis, USA in 1 patient].                                                                                             
Programming: Pacemakers were randomly programmed to either no active pacing (A) RV 
DDD pacing (B) or biventricular DDD pacing (C) in a serial crossover fashion. Patients were 
paced in modalities B and C at a rate of 70 beats/min with a short AV delay of 78 msecs for 
maximal ventricular pre-excitation. Patients were blinded to the pacing mode in an attempt to 
minimise   placebo   effect.                                                                          
Main   outcome   measures                                                                          
Evaluation of patients                                                                                                 
Patients were evaluated in the short term after 4 weeks in each pacing modality. Objective 
exercise tolerance was assessed with treadmill exercise testing from which responders were 
defined as patients who had an improvement in exercise capacity. Symptomatic status was 
assessed   using   the   Minnesota   Living   with   Heart   Failure   Questionnaire   [16].   2-D 
echocardiography was performed using a series 5 Vingmed (Vingmed Inc) to assess cardiac 
chamber dimensions and septal thickness. LVOT gradients were measured using Continuous 
Wave Doppler echocardiography. Patients that responded to BIV pacing were subsequently 
left in that modality and long-term follow up was assessed after 5 years of treatment.      
Statistical analysis: Data are expressed as mean ±SD. Pacing parameters were analysed using 
ANOVA and post Hoc with Scheffes f test and a p value of < 0.05 was considered significant.  
Statistical analysis was performed on an Apple Macintosh iBook Computer (Apple Computers 
Inc., Cupertino, CA) using Statview 512+TM (Abacus Concepts, Berkeley, CA)              
Results
A BiV pacemaker was successfully implanted in 8 out of 9 patients.                                       
Baseline characteristics (Table 1)                                                                                 
The mean age was 57±8 years and 75% were male. The mean QRS duration was 132±26ms, 
LVOT gradient 67±25 mmHg, ejection fraction (EF) 67±14% and average interventricular 
septal thickness was 2.0±0.6cm.                                                                                      
Short term end points   (see Table 2)                                                                                     
Six patients (75%) had objective improvements in exercise capacity with RV or BIV pacing 
(responders) and two had no benefit or a reduced exercise capacity (non responders). Of the 
responders, 3 had better exercise capacity with BIV pacing (Group 1) and 3 with RV pacing 
(Group 2). Those that responded to BIV pacing compared to RV pacing tended to be more 
symptomatic (symptoms scores: BIV 79±6, RV 55±45), have have reduced exercise times 
(BIV 113±102 secs, RV 352±20), larger LVOT gradients (BIV 81±19, RV 45±12 mmHg) and 
a longer QRS duration (BIV 145±20, RV 120±36ms) at baseline. Of the non responders, one 
patient had no objective improvement in exercise tolerance with either pacing modality despite 
a symptomatic improvement. Another had worsening of exercise tolerance with pacing despite 
a symptomatic improvement. This would suggest a significant placebo effect in these two 
patients.
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Table 2:  Endpoints: effects of pacing modalities  on clinical, electrocardiographic and 
echocardiographic parameters
†P<0.05 vs no pacing, * P<0.05 vs no pacing and RV pacing
Responders vs Non responders                                                                                                       
There was no significant difference between responders and non responders in terms baseline 
QRS duration (133±30ms, 131±15ms respectively) or exercise times (232±164ms, 219±200), 
however there was a significant difference in baseline LVOT gradient (51mmHg, 25mmHg 
respectively).
Group 1 (BIV responders, n=3)                                                                                                       
3 patients had maximal improvements in exercise time AND symptoms with BIV pacing. 
Baseline QRS was 145±20msecs, increasing to 211±50ms (p<0.05) with RV pacing and 
decreased to 133±50ms with BIV pacing. (p=ns) Baseline exercise time was 113±102 secs 
which was unchanged with RV pacing (105±65 secs) but increased to 205 ±137 secs with BIV 
pacing (p<0.05 vs. no and RV pacing). Symptoms scores progressively reduced (implying less 
symptoms) from 79±6 with no pacing to 69±15 with RV pacing to 35±16 with BIV pacing 
(p<0.05). Similarly there was a progressive fall in the LVOT gradients from 81±19mm Hg 
with no pacing to 48±17 with RV pacing and to 28±4 with BIV pacing (Figure 1). 
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Figure 1: Changes in LV outflow tract gradient in each patient
Group   2   (RV   pacing   optimal)                                                                  
3 patients had better exercise tolerance with RV pacing compared to baseline and BIV pacing. 
Baseline QRS with no pacing was 120±36 msecs, 200±96 msecs with RV pacing and 
121±33msecs with BIV pacing. Baseline exercise time was 352±120 secs increasing to 
516±136 secs with RV pacing (p<0.05) and was 481±113 secs with BiV pacing. Despite better 
exercise times in this group with RV pacing, BIV pacing was associated with a further 
reduction in symptoms scores (55 ±45 at baseline, 36±39 with RV pacing and 26±35 with BiV 
pacing) and LVOT gradient (45±12mmHg at baseline decreasing to 30±4mmHg with RV 
pacing and 21 ±4mmHg with BIV pacing) when compared with RV pacing.           
Long term follow up (see Table 3)                                                                               
Patients were left in the pacing mode, which showed greatest short-term benefit in terms of 
exercise times. Follow up is available on all patients 5 years since device implantation.
Table 3: Long term follow of each patient
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Group 1                                                                                                       
Of the three patients that showed a short-term benefit with BIV pacing one patient died 43 
months after their implant due to a gradual deterioration in LV function with end stage heart 
failure. One patient has deteriorated clinically and had entered the dilated phase of HCM. The 
third patient after an initial improvement deteriorated with development of atrial arrhythmias 
and needed explantation of the system due to pacemaker system infection and currently has a 
single chamber pacemaker.                                                                                         
Group   2                                                                                                  
All 3 patients that were responders to RV pacing remained well. Two have had their 
pacemakers upgraded to ICDs. One at 36 months for non-sustained VT and one at 82 months 
post implant due to syncope, non-sustained ventricular tachycardia (NSVT) and a positive 
family history for sudden cardiac death.                                                                         
Non-responders shortly after LV lead implantation                                         
Of the non-responders, one patient developed NSVT with syncope. At that time is was not 
possible to individually switch off the LV lead, therefore the lead was extracted and upgraded 
to a dual chamber ICD 3 months following implantation. No further VT was documented 
following this during the 5 year follow up. The other patient died of progressive heart failure 
36 months  post implant.                                                                                     
Discussion  
This is the first case series looking at the short term and long term effects of biventricular 
pacing in symptomatic patients with hypertrophic cardiomyopathy. In this small series there 
appeared to be a beneficial short term effect with pacing on exercise times, symptoms and 
outflow tract gradients in some but not all highly symptomatic patients. Of those with 
objective short term benefit, 50% appeared to have an incremental benefit from BIV pacing 
associated with a dramatic reduction in left ventricular outflow tract gradients. The mechanism 
of benefit from biventricular pacing in this small group of patients is unclear. Part of its 
beneficial effect could be related to alteration of the left ventricular contraction pattern. 
Simultaneous activation of the right and left posterolateral wall (the site of the LV pacing lead) 
would cause earlier apical contraction and later activation of the basal septum which could 
result in a decrease in the LVOT gradient. Those benefiting from BIV pacing had more severe 
exercise limitation, worse symptoms and larger outflow tract gradients. BIV pacing appeared 
to have an incremental effect on LVOT gradients over RV pacing alone. In one patient 
implanted with a device capable of independently altering VV timings it was possible to alter 
the gradient depending on the relative timing of LV and RV activation with greatest gradient 
reduction when LV was paced 4 msecs prior to the RV, with earlier LV activation times being 
not as effective in reducing the gradient. Of the patients with short term improvements from 
BIV pacing, two developed progressive LV dysfunction. This may simply represent the natural 
history in these patients with the severe forms of HCM degenerating into the dilated phase of 
their disease, rather than an effect of BIV pacing.                                          
Other points of note are the fact that several of the patients subsequently had ICDs and in one 
patient there was the suggestion that LV pacing may have been arrhythmogenic with non-
sustained VT developing, which improved after LV lead extraction.                        
RV pacing and hypertrophic cardiomyopathy - previous studies                                           
Dual chamber RV pacing was initially proposed as an alternative therapy for symptomatic 
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patients with hypertrophic cardiomyopathy. Its beneficial effects were thought to be explained 
by alteration of LV depolarization and optimization of atrial contraction [9,10]. Initial 
uncontrolled studies suggested significant beneficial effects of dual chamber pacing on LVOT 
gradients and symptomatic status [11]. However later randomised studies produced conflicting 
results. Kappenberger et al [5,12], in a study of 83 patients showed improved symptoms, 
exercise duration and LVOT gradients with RV pacing. Nishimura et al, in a double blind 
randomised crossover trial recruited 21 patients with severe symptoms of HCM and showed 
that dual chamber (RA and RV) pacing relieved symptoms and decreased gradients in some 
patients however in others symptoms didn't change or worsened [6]. In addition it was noted 
that chronic DDD pacing while reducing obstruction may exacerbate diastolic dysfunction is 
these patients [13,14]. Symptomatic improvements also occurred from implantation of the 
pacemaker without its haemodynamic benefit, suggesting a significant placebo effect. Maron 
et al, studied the effect of dual chamber pacing in 48 symptomatic HCM patients all with 
LVOT gradients greater than 50 mm Hg at rest [15]. Six months of unblinded pacing in these 
patients resulted in functional class and quality of life improvements but no change in peak 
oxygen consumption. The authors concluded that symptomatic improvement was more 
consistent with a placebo effect. Modest reductions in outflow gradient were achieved in most 
patients with a small subset of patients over 65 years of age showing a clinical response, 
suggesting that DDD pacing could be a therapeutic option for some elderly patients.  
BIV pacing and hypertrophic cardiomyopathy                                                                         
Biventricular pacing has been shown to be beneficial in symptomatic patients with heart 
failure, with a number of studies demonstrating improved morbidity, mortality and its effects 
on   reverse   remodeling   [16-30].   In   view   of   these   results,   case   studies   were   reported 
demonstrating   the   beneficial   effect   of   biventricular   pacing   in   end-stage   hypertrophic 
cardiomyopathy (severely impaired left ventricular function). Pezzulich et al, [31] reported a 
case of a 43 year old with severely impaired LV systolic function and hypertrophic 
cardiomyopathy. Following biventricular pacing there was a significant improvement in 
clinical status, left ventricular ejection fraction and peak VO2. A similar case report was later 
reported in a 42 year old patient with dilated-hypokinetic hypertrophic cardiomyopathy [32]. 
Following this a study of twenty patients with non-obstructive HCM and symptoms of heart 
failure and effects of biventricular pacing was reported by Elliot et al [33]. After a mean 
follow up of 13 months, improvement in symptoms was reported in 40% of patients. This was 
associated with an increase in ejection fraction, a reduction in left ventricular end-diastolic 
diameter and left atrial diameter. There was however no change in peak oxygen consumption 
during   exercise.                                                                                    
We reported the first case of the beneficial effect of biventricular pacing in a symptomatic 
patient with hypertrophic cardiomyopathy, preserved LV systolic function and a significant 
LVOT gradient [8]. We found a significant improvement in symptomatic status, exercise times 
and haemodynamics over and above that produced by RV DDD pacing and far superior to no 
pacing. Following this three case reports were published demonstrating its beneficial effect on 
symptomatic patients with HCM in children and adults [34-36].                                     
Limitations
This is a small series of patients and thus it is difficult to generalise the results. The patients 
who appeared to show a short term benefit with BIV pacing were a highly symptomatic group 
with significant electrical dyssynchrony. There also appeared to be a placebo effect in some 
patients who were paced. No measure of mechanical dyssynchrony were made with tools such 
as Doppler tissue imaging and therefore it is unclear as to whether improvements with BIV 
pacing were related to improved mechanical synchronisation. Also as the majority of devices 
were unable to program independent VV timing it is unclear as to whether optimisation of 
such   timings   with   echocardiography   may   have   been   able   to   provide   further   benefit.
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Conclusion
We have shown short-term objective improvements in a small sub group of patients with HCM 
with the use of BIV pacing. With longer term follow up this benefit does not appear to be 
sustained. These findings require further investigation in a larger patient population in a 
randomised manner in the current era of devices with independent V-V programming to 
ascertain a potential mechanism of benefit.                                                             
Biventricular pacing could therefore become an attractive alternative for alcohol septal 
ablation or surgical ablation in symptomatic patient with hypertrophic cardiomyopathy, 
especially   in   subjects   requiring   an   ICD.                                                            
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